JF

08

Nov2017

The pan-Canadian Pharmaceutical Alliance (pCPA): Negotiations Status Update

The pan-Canadian Pharmaceutical Alliance (pCPA) updated the status of negotiations on brand name drugs as of October 31, 2017: 46 negotiations are currently underway with 2 new files added since the last update of September 30, 2017: Gazyva (obinutuzumab): Used to treat follicular lymphoma Lynparza (olaparib): Used to treat ... Read More

08

Nov2017

INESSS Releases Additional Information on the Continuous Evaluation Process

On November 7, 2017, Québec’s Institut national d’excellence en santé et en services sociaux (INESSS) released a notice to manufacturers announcing further details on the continuous evaluation process. INESSS would like to inform manufacturers that as of November 1, 2017, new terms and conditions apply for manufacturers who wish to request ... Read More

08

Nov2017

National Pharmacare: No need for “Repeal & Replace” Canadian edition

The ongoing debate about repealing existing public and private drug programs and replacing them with a one-size-fits-all national pharmacare program returned to the headlines with the release of a wide-ranging report from the Parliamentary Budget Officer (PBO) which estimates the cost of a federally administered universal pharmacare plan. The PBO study ... Read More

03

Nov2017

INESSS Releases List of Drug Products Currently Being Reviewed Under the Continuous Evaluation Process

On November 2, 2017, Québec’s Institut national d’excellence en santé et en services sociaux (INESSS) announced they have now published the list of drug products currently undergoing review under their new continuous evaluation process on their website. Citizens, health professionals, patients and their caregivers, as well as their associations or ... Read More

01

Nov2017

PMPRB 2016 Annual Report Released

The Patented Medicine Prices Review Board (PMPRB), in accordance with sections 89 and 100 of the Patent Act, released its Annual Report for the year ended December 31, 2016. The Annual Report is an extensive document that reviews all of the PMPRB’s major activities, analyses of the prices of patented ... Read More

31

Oct2017

PDCI is excited to announce another great addition to the PDCI team: John-Paul Dowson, Director, Reimbursement Strategy

It is with great pleasure to announce after several months of a successful strategic partnership with Roubaix Strategies Inc. (RSI), John-Paul Dowson is formally joining the PDCI team as our new Director of Reimbursement Strategy. John-Paul brings more than 20 years of senior experience working in the health and pharmaceutical sectors. ... Read More

30

Oct2017

PDCI Welcomes Jennifer Haig as Manager, HTA and Health Economics

We are pleased to announce that effective October 30, 2017 Jennifer Haig has joined PDCI Market Access Inc. as Manager, HTA and Health Economics. Jen joins our growing HTA team and brings extensive experience with Pharmacoeconomic and Budget Impact modelling. Prior to joining PDCI, Jen was a market access and health ... Read More

18

Oct2017

RAMQ: October 2017 Update for the List of Medications

The Régie de l’assurance maladie du Québec (RAMQ) released its October update of the List of Medications on October 18, 2017, effective immediately. For more information and to see the list update schedule, please visit the RAMQ website.

17

Oct2017

INESSS Releases Additional Information on the Continuous Evaluation of Drug Products – Mandatory Notification

On October 12, 2017, Québec’s Institut national d’excellence en santé et en services sociaux (INESSS) released a notice to manufacturers announcing the details on the process for the mandatory notification required for submissions. As of November 1, 2017, manufacturers are required to inform INESSS at least 2 months in advance ... Read More

12

Oct2017

CADTH Common Drug Review Releases New Update

On October 11, 2017, the Canadian Agency for Drugs and Technologies in Health (CADTH) released a new CDR Update (Issue 129). Based on feedback from stakeholders, CADTH will be implementing the proposed revision to the resubmission eligibility criteria and a new randomized controlled trial will no longer be required ... Read More